Leukemia Research
Volume 26, Issue 11 , Pages 993-996 , November 2002

Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients

Received 8 October 2001 ,Accepted 18 February 2002.

References 

  1. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al.  (FAB cooperative group)—Proposals for classification of the myelodysplastic syndrome. Br. J. Haematol. 1982;51:189–199
  2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink K, Vardiman J, et al.  World health organization classification of neoplastic diseases of the hematopoietic, World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committe meeting—Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999;17(12):3835–3849
  3. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin. Haemotol. 1996;33(2):127–138
  4. Bernell P, Jacobsson B, Nordgren A, Hast R. Clonal cell lineage involvement in myelodysplastic syndrome studied by fluorescence in situ hybridization and morphology. Leukemia. 1996;10:662–668
  5. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. Cytogenetic clonality in myelodysplastic syndrome studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood. 1993;81(6):1580–1585
  6. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, et al.  International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood. 1997;89(6):2079–2088
  7. Luke S, Varkey JA, Belogolovkin V, Ladoulis CT. Current state of fluorescence in situ hybridization (FISH) in diagnostic pathology. Cell Vision. 1997;4(7):16–31
  8. Gozzetti A, Le Beau MM. Fluorescence in situ hybridization. Uses and limitations. Semin. Hematol. 2000;37(4):320–333
  9. Jenkins RB, Le Beau MM, Kraker WJ, Borell TJ, Stalboerger PG, Davis EM, et al.  Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood. 1992;79(12):3307–3315
  10. Zhao L, Oort JV, Cork A, Liang JC. Comparison between interphase and metaphase cytogenetics in detecting chromosome defects in hematological neoplasias. Am. J. Hematol. 1993;43:205–211
  11. Kibbelar RE, Mulder JWR, Dreef EJ, Van Kamp H, Fibbe WE, Wessels JW, et al.  Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: a comparison of banding and fluorescence in situ hybridation. Blood. 1993;82(3):904–913
  12. Tanaka K, Arif M, Eguchi M, Shintani MM, Kumaravel T.S., Asaoku H, et al. Interphase flurescence in situ hybridization overcomes pitfalls of G-banding analysis with special references to underestimation of chromomal aberration rates, Cancer Genet Cytogenet 1999;115:32–8.
  13. Schröck E, Padilla-Nash H. Spectral karyotyping and multicolor fluorescence in situ hybridization reveal new tumor-specific chromosomal aberration. Semin. Hematol 2000;37(4):334–47.
  14. Engel H, Drach J, Keyhani A, Jiang S, Van NT, Kimmel M, et al.  Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndrome in complete remission by molecular cytogenetics of progenitor cells. Leukemia. 1999;13:568–577
  15. Chauffaille ML, Figueiredo MS, Beltrani R, Antunes SV, Yamamoto M, Kerbauy J. Acute promyelocytic leukemia: the sutdy of t(15;17) translocation by FISH, RT-PCR and cytogenetic techniques. Braz. J. Med. Biol. Res. 2001;34(6):735–743
  16. F. Mitelman, editor. ISCN: An international system for human cytogenetic nomenclature. Basel: S. Karger, 1995.
  17. Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CDL, Daiton M, et al.  Fluorescence in situ hybridization analysis of t(3;12)(q26;q13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic synrome. Blood. 1996;88(2):682–689
  18. Geddes AD, Bowen DT, Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br. J. Haematol. 1990;76:194–202
  19. Harbott J, Mancini M, Verellen-Dumoullin CH, Moorman AV, Secker-Walker LM. Hematological malignancies with a deletion of 11q23: cytogenetic and clinical aspects. Leukemia. 1998;12:823–827

PII: S0145-2126(02)00047-4

Leukemia Research
Volume 26, Issue 11 , Pages 993-996 , November 2002

Article Tools